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ABSTRACT
Cancer cell metabolism is required to support the biosynthetic demands of cell 
growth and cell division, and to maintain reduction oxidaton (redox) homeostasis. This 
study was designed to test the effects of glucose and glutamine on ovarian cancer cell 
growth and explore the inter-relationship between glycolysis and glutaminolysis. The 
SKOV3, IGROV-1 and Hey ovarian cancer cell lines were assayed for glucose, pyruvate 
and glutamine dependence by analyzing cytotoxicity, cell cycle progression, apoptosis 
and ATP production. As determined by MTT assay, glucose stimulated cell growth while 
the combination of glucose, glutamine and pyruvate resulted in the greatest stimulation 
of cell proliferation. Furthermore, 2-deoxy-glucose (2-DG) and 3-bromopyruvate (3-BP) 
induced apoptosis, caused G1 phase cell cycle arrest and reduced glycolytic activity. 
Moreover, 2-DG in combination with a low dose of aminooxyacetate (AOA) synergistically 
increased the sensitivity to 2-DG in the inhibition of cell growth in the ovarian cancer 
cell lines. These studies suggest that dual inhibition of glycolysis and glutaminolysis 
may be a promising therapeutic strategy for the treatment of ovarian cancer.
INTRODUCTION
Ovarian cancer is the leading cause of death among 
gynecological malignancies and remains the 5th leading 
cause of cancer death among women in the United 
States [1]. Almost 75% patients with ovarian cancer are 
diagnosed with late stage disease. The initial treatment 
for advanced stage ovarian cancer frequently includes 
a surgical staging or debulking procedure followed by 
combination platinum and taxol adjuvant chemotherapy 
[2,  3].  Despite  a  high  response  rate  to  first-line 
chemotherapy, the majority of women with advanced stage 
ovarian cancer will relapse, with a median progression 
free survival (PFS) being 16 months after initial diagnosis. 
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Further, 5 year survival is dismal at less than 40% [4, 5]. 
Therefore, new treatment strategies are urgently needed to 
improve outcomes in women with ovarian cancer.
The relationship between energy metabolism and 
tumorigenesis has been appreciated for several decades 
when Dr. Otto Warburg first described aerobic glycolysis 
as a metabolic hallmark of cancer metabolism [6]. Cancer 
cell metabolism is necessary to fuel the biosynthetic 
demands of cell growth, cell division and to maintain 
redox homeostasis. These changes in metabolism are, in 
fact, a direct result of the metabolic reprogramming of 
cells controlled by oncogenes and tumor suppressor genes 
[7, 8]. Regardless of the presence of adequate oxygen, 
cancer cells selectively utilize glycolysis over oxidative 
phosphorylation. Aerobic glycolysis in cancer cells utilizes 
glucose and glutamine as the primary carbon sources for 
ATP production and biosynthesis. Although cancer cells 
exhibit high rates of glycolysis, their mitochondrial 
oxidative phosphorylation remains intact and becomes 
progressively more dependent on glutamine metabolism 
to provide intermediates of the tricarboxylic acid (TCA) 
cycle to feed other biosynthetic pathways [7, 9].
Epidemiologic data show an increase risk of ovarian 
cancer in patients with type 2 diabetes [10]. Additionally, 
ovarian cancer patients with diabetes have been shown to 
have poorer survival [11]. Recent studies have confirmed 
that ovarian surface epithelial cells of mice representing 
early (benign), intermediate, and late (aggressive and 
invasive) stages of ovarian cancer display an increasingly 
glycolytic phenotype, suggesting that glycolysis is integral 
to the development and progression of ovarian cancer [12, 
13]. Inhibition of glucose uptake or targeting the glycolytic 
pathway  has  shown  promising  anti-cancer  effects  in 
ovarian cancer cells and pre-clinical mouse models [14–
16]. Quantitative metabolic parameters measured on FDG 
PET/CT at  the time of  the first relapse have significant 
predictive  values  for  post-relapse  survival  in  ovarian 
cancer [17]. In addition, we have recently demonstrated 
that restriction of glutamine or inhibition of glutaminase 
by compound 968 induces apoptosis and cell cycle arrest 
in ovarian cancer cells [18, 19]. Taken together, these data 
suggest that glycolysis and glutaminolysis are critically 
important in the pathogenesis of ovarian cancer. Thus, the 
aim of this study was to investigate the effects of glucose 
and glutamine on proliferation in ovarian cancer cells, and 
determine the potential of targeting glucose and glutamine 
metabolism as a promising therapeutic strategy for ovarian 
cancer.
RESULTS
Glucose is essential for cell survival
We have previously shown that glucose is essential 
for the growth and survival of endometrial cancer cells 
[20]. To explore whether glucose modulates cell survival 
in ovarian cancer cells, we examined the effects of 
glucose alone on cell proliferation in three epithelial 
ovarian cancer cell lines. The SKOV3, IGROV-1 and Hey 
cells were cultured in their standard culture media with 
four concentrations of glucose (0, 2.5, 5.5 and 25 mM) 
for 72 hours. 5 mM glucose in the media corresponds to 
normal physiological levels in human blood (100 mg/dl), 
whereas 25 mM glucose is equivalent to a patient with 
severely uncontrolled diabetes [20]. Glucose effectively 
promoted cell proliferation in a dose dependent manner 
in all three cell lines (Figure 1A). To further examine 
how glucose  affects  energy flux,  the  cellular  levels of 
ATP and lactate were measured in the ovarian cancer 
cells. Incubation in various glucose concentrations for 
24 hours revealed that increasing glucose concentrations 
significantly  increased  cellular  ATP  level  and  lactate 




AMP-activated  protein  kinase  (AMPK)  and  the 
mammalian target of rapamycin (mTOR) are important 
protein kinases in maintaining cellular energy homeostasis 
and glucose metabolism in cancer cells [20, 21]. To 
investigate the mechanisms underlying the regulation 
of cell proliferation by glucose, we characterized the 
effect of glucose on the AMPK and mTOR/S6 signaling 
pathways. Glucose decreased phosphorylation of AMPK 
and increased phosphorylation of S6 in a dose-dependent 
manner in ovarian cancer cells within 24 hours after 
exposure (Figure 1D). These results indicate that the 
AMPK and mTOR/S6 pathways are involved in glucose 
metabolism in ovarian cancer.
Glucose, glutamine and pyruvate are the main 
nutrient sources used by cancer cells for biosynthesis, 
growth and survival [9]. To further validate the energy 
source of cell proliferation in ovarian cancer cells, the 
three cell lines were treated with the glucose (5.5 mM), 
glutamine (4.0 mM) or pyruvate (5.0 mM) alone or in 
combination  in glucose/glutamine/pyruvate-free culture 
media for 48 hours. Cell death resulted in all three cell 
lines when cultured for 5 days under conditions of glucose 
starvation; cell death of these cell lines was continued 
to be induced even when their media was subsequently 
supplemented with glutamine and/or pyruvate (data 
not  shown).  Glucose  alone  can  significantly  maintain 
cell growth in all three ovarian cancer cell lines. In the 
absence of glucose in the culture media, either glutamine 
or pyruvate can temporarily maintain cell survival but 
for only 48 hours. All cell lines exhibited maximal cell 
proliferation in the media containing the mixture of 
glucose, glutamine and pyruvate (Figure 1E). Together, 
these results confirm that for these ovarian cancer cells, 
glycolysis is the main source of energy production, and 
glucose is the most critical nutrient for cell proliferation 
and survival.
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Glucose deprivation induces apoptosis in ovarian 
cancer cells
To elucidate the mechanisms of glucose on 
cell growth, the effect of different concentrations of 
glucose on the induction of apoptosis was analyzed. 
SKOV3, IGROV-1 and Hey cells were treated with four 
concentrations of glucose in their standard media for 
14 hours. The expression of Annexin V was increased 
distinctly under glucose deprivation compared to 25 mM 
glucose treatment (high glucose condition) in all three cell 
lines (Figure 2A). To further validate the effect of glucose 
on apoptosis pathways, ELISA assay analysis was used 
to detect the activity of cleaved caspase-3. Incubation of 
cells with glucose deprivation for 10 hours significantly 
increased cleaved caspase3 activity by approximately 
80 to 120% in these three cell lines compared with the 
normal glucose groups (Figure 2B). Western blotting 
indicated that glucose deprivation decreased BCL-2 and 
MCL-1 protein expression in a dose dependent manner 
in all three cell lines (Figure 2C). To further analyze the 
role of glucose on the mitochondrial apoptosis pathway, 




complete blockage of glucose deprivation induced cleaved 
caspase-3  activity  in  the Hey  cells  (Figure  2D). These 
findings  suggest  that  inducing mitochondrial  apoptosis 
may be a major mechanism to inhibit cell proliferation 
in ovarian cancer cells under glucose deprivation or low 
glucose conditions.
Figure 1: Glucose and glutamine are two major nutrients for cell proliferation in ovarian cancer cells. The ovarian cancer 
cell lines SKOV3, IGROV-1 and Hey were treated in glucose free media supplemented with various concentrations of glucose (0, 2.5, 
5.5, and 25 mM) for 48 hours. Cell proliferation was assessed by MTT assay. Glucose promoted cell proliferation (A), increased ATP (B) 
and lactate production (C) in all three cell lines. The expression of phosphorylation of p-AMPK and p-S6 in SKOV3, IGROV-1 and Hey 
cells was detected by Western blotting after treatment with glucose for 24 hours (D). The three cell lines were grown for 48 hours in media 
lacking glucose, glutamine or pyruvate supplemented with glucose (5.5 mM), glutamine (4.0 mM) or pyruvate (5.0 mM), respectively, or a 
combination of these as indicated (E). The combination of glucose, glutamine and pyruvate caused maximal cell proliferation. The results 
are shown as the mean ± SEM of triplicate samples (*P<0.05, **p < 0.01) and are representative of three independent experiments.
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Glucose deprivation induces cell cycle G1 arrest 
in ovarian cancer cells
To further confirm whether cell growth inhibition 
induced by glucose deprivation or low glucose, was 
related  to  cell  cycle  arrest,  the  cell  cycle  profile  was 
analyzed by Cellometer after treating the SKOV3, 
IGROV-1  and  Hey  cells  with  four  concentrations  of 
glucose (0, 2.5, 5.5 and 25.0 mM) for 36 hours. The 
depletion of glucose increased the G1 population from 
56% to 72% in SKOV3 cells, from 58% to 75% in 
IGROV-1  and  from  61%  to  81%  in  Hey  cells  when 
compared with normal glucose groups (5.5 mM). The S 
phase gradually increased with increasing concentrations 
of glucose in the three cell lines (Figure 3A). To further 
explore the effects of glucose on cell cycle checkpoints, 
the cells were cultured with the four concentrations of 
glucose for 24 hours. The results of western blot analysis 
showed that the expressions of both cyclin D1 and CDK4 
increased, and p21 decreased with increasing glucose 
concentrations (Figure 3B). These results suggest that 
glucose promotes the passage of cells into S phase from 
G1 phase.
Inhibition of glycolysis or glutaminolysis reduced 
cell proliferation in ovarian cancer cells
To further analyze the effect of targeting glycolysis 
or glutaminolysis on cell growth in ovarian cancer cells, 
we treated the cells with two glycolysis inhibitors, 2-DG 
and 3-BP, and one glytaminolysis inhibitor, AOA. 2-DG 
is a glucose analogue that is unable to undergo glycolysis, 
and 3-BP targets both hexokinase-II (HK-II) and GAPDH 
in the glycolytic pathway [22]. AOA is a general inhibitor 
of  pyridoxal  phosphate-dependent  enzymes  including 
transaminases that are involved in amino acid metabolism 
[23]. Varying  concentrations  of  2-DG,  3-BP  and AOA 
resulted in a dose dependent inhibition in cell growth in 
all three cell lines after 48 hours of treatment (Figure 4A). 
Consistent with their assumed antiglycolytic effects, 2-DG 
and 3-BP were able to increase the glucose concentration 
and reduce cellular lactate production in a dose dependent 
Figure 2: Depletion of glucose induces apoptosis in ovarian cancer cells. The SKOV3, IGROV-1, and Hey cells were cultured 
with different concentrations of glucose (0, 2.5, 5.5, and 25 mM) for 14 hours. Glucose deprivation induced Annexin V expression (A) 
and increased cleaved caspase-3 activity (B). Expression levels of Mcl-1 and Bcl-2 were analyzed by Western blot (C). Hey cells were 
pre-treated using V-ZAD (20 mM) for 2 hours, and then treated with glucose (0, 5.5 mM). V-ZAD reduced cleaved caspase-3 activity 




3-BP  significantly  reduced glucose  consumption  in  the 
ovarian cancer cells (Figure 4B and 4C).
To evaluate the underlying mechanism of growth 
inhibition by 2-DG, 3-BP, and AOA, the effects of these 
inhibitors on cell apoptosis was analyzed using Annexin V 
assay. All three inhibitors significantly increased Annexin 
V expression in a dose dependent manner after 18 hours of 
treatment (Figure 4D). Analysis of cell cycle showed that 
only 2-DG caused a G1 phase arrest in the cells (Figure 
4E) while 3-BP and AOA did not induce any changes in 
cell cycle even following incubation of the cells for 48 
hours (data not shown). Together, these results indicate 
that targeting glycolytic or glutaminolytic pathways 
effectively inhibit cell growth in ovarian cancer cells.
AOA synergizes with 2-DG to decrease cell 
proliferation in ovarian cancer cells
We have previously shown that inhibition of 
glutaminolysis results in a significant increase in glucose 




and 50 ug/ml) alone or a combination of the two for 72 
hours. Cell proliferation was assessed by MTT assay. 
As expected, 2-DG alone  resulted  in a decrease  in cell 
proliferation. Combining AOA with  2-DG  at  indicated 
concentrations, led to synergistic inhibitory effects in 
all three ovarian cancer cell lines (Figure 5A-5C, CI<1). 
These results suggested that inhibition of glutaminolysis 
results in increased sensitivity of ovarian cancer cells to 
glycolysis inhibitor 2-DG.
DISCUSSION
In this study, we determined that glucose is the 
most important energy source in cell proliferation 
and investigated the potential role that glucose has in 
modulating cell growth in ovarian cancer cells. Our 
results show that the administration of glucose promotes 
cell growth though the inhibition of AMPK, the activation 
of mTOR/S6 pathways, the reduction of apoptosis and 
an increase in cell cycle S phase with corresponding 
increases in ATP and lactate production. In addition, 
targeting glycolysis with 2-DG and 3-BP, and targeting 
glutaminolysis with AOA effectively inhibit ovarian 
cancer cell proliferation. Moreover, AOA treatment 
resulted in significant synergy when combined with 2-DG 
to inhibit cell proliferation in ovarian cancer cells. These 
results support the concept for simultaneous targeting of 
glycolysis and glutaminolysis as a valuable strategy for the 
treatment of ovarian cancer.
Regardless of the availability of oxygen, cancer cells 
utilize high rates of glycolysis and lactate fermentation. 
This  dependence  on  glucose  utilization  may  reflect 
the fact that cancer cells are more sensitive to glucose 
stimulation than normal cells due to a higher consumption 
ratio of energy [20, 24]. The combination of glycolysis 
and glutaminolysis supports rapid proliferation of cancer 
cells through production of ATP and other biosynthetic 
precursors  [25].  However,  glycolysis  alone  yields 
enough energy to facilitate cancer cell growth despite 
mitochondrial defects [7]. Recent studies have confirmed 
that the response of cancer cells to glucose starvation 
is mainly dependent on the cell genetic and epigenetic 
background [26, 27]. The majority of cancer cells exhibit 
energy crisis under glucose deprivation viaactivation of 
Figure 3: Glucose affects cell cycle progression in ovarian cancer cells. The SKOV3, IGROV-1, and Hey cells were treated in 
glucose-free media supplemented with various concentrations of glucose (0, 2.5, 5.5, and 25 mM) for 36 hours. Cell cycle analysis was 
performed using Cellometer assay (A). The effects of glucose on cyclin D1, CDK4 and p21 were examined by Western blot after exposure 
to glucose for 24 hours at the indicated concentrations (B). Data are representative of three independent experiments.
Oncotarget63556www.impactjournals.com/oncotarget
cell death pathways that lead to apoptosis, cellular stress 
and cell cycle arrest [20, 28, 29]. Glucose deprivation 
induces G1 phase arrest and apoptosis in endometrial, 
breast, leukemia, prostate and lung cancer cells [20, 21, 
27, 30–32]. However, in N-GlcNAc2-modified protein-
producing renal carcinoma and bladder cancer cells, G2/
M-phase arrest was seen following glucose deprivation 
[33, 34]. In this study, we evaluated the impact of glucose 
on cell cycle arrest and apoptosis in three ovarian cancer 
cell lines. Our results indicate that in these ovarian cancer 
cells, glucose deprivation causes inhibition of ovarian 
cancer cell growth through the induction of G1 phase 
cell cycle arrest and apoptosis as seen with augmented 
Annexin-V expression, along with decreased expression 
of CDK4, cyclin D1, MCL-1, BCL-2 and increased p21 
expression. These results are consistent with our recent 
study in endometrial cancer [20] and suggest that the anti-
proliferative effect induced by deprivation of glucose is 
associated with cell cycle arrest and apoptosis in ovarian 
cancer cells.
In the present study, we identified energy sources 
for cell proliferation in order to characterize the processes 
involved by targeting glycolysis and glutaminolysis in 
ovarian cancer. The growth of ovarian cancer cells relies 
primarily on glucose, although the tested cell lines exhibit 
different degrees of response to glucose stimulations. 
Either  pyruvate  or  glutamine  briefly  keep  the  cells 
growing under conditions of glucose deprivation, and the 
combination of glucose, glutamine and pyruvate results in 
the greatest amount of cell proliferation. These findings 
suggest that the glycolytic pathway is the most important 
for energy generation and cell survival in ovarian cancer.
There are several approaches to disrupting glycolysis 
including targeting glucose transport, glycolytic processes, 
genes or pathways related to glycolytic metabolism [7, 9]. 
2-DG  is  a  reliable glycolysis  inhibitors  and a potential 
anti-tumorigenic agent [9, 35, 36]. Inhibition of glycolysis 
by  2-DG  leads  to  decreased  cellular  ATP  production, 
induction of cell cycle arrest, increased apoptosis and 
inhibition  of  cell  proliferation  in  cancer  cells  [37–40]. 
Figure 4: The effect of 2-DG, 3-BP and AOA on cell growth in ovarian cancer cells. The SKOV3, IGROV-1, and Hey cells 
were treated with 2-DG, 3-BP and AOA for 48 hours as indicated. Cell proliferation was assessed by MTT assay. 2-DG, 3-BP and AOA 
reduced cell proliferation in a dose dependent manner (A). 2-DG and 3-BP reduced lactate production and glucose consumptions in the 
media after 24 hours of treatment (B and C). 2-DG, 3-BP and AOA increased the expression of Annexin V after 18 hours of treatment (D). 
2-DG induced cell cycle G1 arrest in all three cell lines (E). Data are shown as the mean ± SEM of triplicate samples and are representative 
of three independent experiments.
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Figure 5: AOA increased sensitivity to 2-DG in inhibition of cell proliferation. The SKOV3, IGROV-1, and Hey cells were 
cultured overnight and subsequently treated with AOA (5 ug/ml) alone and in combination with varying concentrations of 2-DG (1, 5, 25 
and 50 ug/ml) for 72 hours. AOA synergistically enhanced anti-proliferative effect of 2-DG in ovarian cancer cells (A-C). Data are shown 




3 activity, activation of AMPK and inhibition of AKT 
phosphorylation [41, 42]. The 3-BP mediated inhibition 
of glycolysis occurs mainly through targeting hexokinase-
II  (HK-II)  and GAPD, which  allows  3-BP  to  decrease 
the production of ATP, induce apoptosis, increase ROS 
and consequently cause growth inhibition in cancer cells 
including ovarian cancer [43]. The results of this study 
show that 2-DG and 3-BP have potent inhibitory effects 
along with induction of apoptosis on ovarian cancer cells 
that are comparable to glucose deprivation. Furthermore, 
increased extracellular glucose and decreased lactate 
production indicated that both 2-DG and 3-BP efficiently 
block glycolysis. Interestingly, in all three ovarian cancer 
cell lines, 2-DG treatment induced cell cycle arrest in G1 
phase while 3-BP did not have this effect, suggesting that 
these two agents inhibit cell growth via different cytotoxic 
mechanisms.
Cancer cells utilize glucose and glutamine as primary 
carbon sources to feed mitochondrial intermediates 
for biosynthetic precursor. A recent study found that 
proliferating cells grown under hypoxic conditions rely 
almost exclusively on the reductive carboxylation of 
glutamine-derived α-ketoglutarate for de novo lipogenesis 
[44]. Our previous study in ovarian cancer cells found that 
either the deprivation of glutamine or the inhibition of 
glutaminolysis  by  compound 968  significantly  reduced 
cell proliferation and induced apoptosis through AMPK/
mTOR/S6 pathway [18, 19]. Therefore, it is possible 
that the combined inhibition of the reductive glutamine 
pathway together with inhibition of glycolytic flux would 
block multiple biosynthetic pathways and energy sources. 
This blockage may in turn lead to enhanced or synergistic 
inhibition of cancer cell viability. Indeed, the addition of 
metformin  to  2-DG  inhibited mitochondrial  respiration 
and glycolysis in prostate cancer cells leading to a severe 
depletion in ATP [45]. The combination of metformin 
and 2-DG was much more inhibitory towards cancer cell 
proliferation than treatment with metformin or 2DG alone 
[45]. In the current study, we found that AOA inhibited 
cell growth in a dose dependent manner in ovarian cancer 
cells. Further, compared to each agent alone, combination 
of low dose AOA and serial doses of 2-DG lead to a strong 




innovative therapeutic strategy for ovarian cancer.
MATERIALS AND METHODS
Cell culture and reagents
The human ovarian cancer cell lines SKOV3, 
IGROV-1  and  Hey  were  used.  The  Hey  and  SKOV3 
cells were purchased from ATCC (American Type 
Culture Collection, USA). The  IGROV-1  cell  line was 
provided by Dr Jazaeri from the Department of Obstetrics 
and Gynecology,  University  of Virginia.  The  Hey  and 
IGROV-1  cell  lines  were  maintained  in  RPMI-1640 
medium (cat # 21870-076, Gibco, USA) supplemented 
with 5% and 10% fetal bovine serum (FBS), respectively. 
The SKOV3 cell line was maintained in DMEM/(cat # 
11966-025,  Gibco,  USA)  medium  supplemented  with 
10% FBS. For glucose studies, the cells were cultured in 
their standard maintenance medium containing 5% FBS 
and supplied with various concentrations of glucose (0, 
2.5, 5.5, and 25.0 mM). All media was supplemented with 





diphenyl-2H-tetrazolium  bromide  (MTT),  glucose 
solution, RNase A, 3-BP and AOA were purchased from 
Sigma-Aldrich (St. Louis, MO). The 2-DG and ATP assay 
kits were purchased from AAT Bioquest (Sunnyvale, CA). 
The Annexin V FITC kit was purchased from Biolegend 
(San  Diego,  CA).  The  anti-phosphorylated  (phospho)-
AMPK,  anti-pan-AMPK,  anti-phospho-S6,  and  anti-
pan-S6 antibodies were all purchased from Cell Signaling 
(Beverly, MA). Enhanced chemiluminescence (ECL) 
detection reagents were purchased from GE Health Care 






cultured in media containing different concentrations of 
glucose for 48 hours. Cell proliferation was measured 
by adding 5 ul MTT solution (5 mg/ml) per well for an 
additional 1 hour incubation. The MTT reaction was 
terminated by replacing the media with 100 ul DMSO. 
Viable cell densities were determined by measuring 
absorbance of metabolic conversion of the colorimetric 
dye  at  570  nm  (Tecan,  Morrisville,  NC).  Each 
experiment was performed in triplicate and repeated 
three times.
L-Lactate assay
Production  of  L-lactate  was  measured  using  the 
L-Lactate  Assay  Kit  (Eton  Bioscience,  San  Diego, 
CA).  Briefly,  the  cells  were  treated  with  increasing 
concentrations of glucose, 2-DG and 3-BP for 24 hours. 
Next,  10  ul  of  the  culture  medium  was  transferred 
into  a  new  96-well  plate;  40  ul  of  distilled water was 
subsequently added to each well. An additional 50 ul of 
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glucose assay solution was added to each well, and the 
plates were incubated for 30 min at 37°C without CO2. 
Lactate levels were measured at a wavelength of 490 
nm using a plate reader from Tecan. The experiments 
were performed in triplicate and repeated twice to assure 
consistency.
Glucose assay
The concentrations of glucose in the media were 
detected by the Glucose Assay Kit from Eton Bioscience, 
following the manufacturer’s instruction. After treatment 
of the cells with 2-DG and 3-BP for 24 hours, 10 ul of 
the culture medium and 40 ul distilled water were added 
into a new 96 well plates. An additional 50 ul of glucose 
assay solution was added to each well, and the plates 
were incubated for 15 min at 37°C without CO2. 50 μl of 
stop solution (0.5 M acetic acid) was added to each well 
immediately after incubation, followed by brief gentle 
agitation. Glucose levels were measured at 490 nm using 
a Tecan plate reader. Each experiment was performed in 
triplicate and repeated twice.
ATP assay
The levels of cellular ATP was assessed using the 
Luminometric ATP Assay Kit. Briefly, cells were treated 
with glucose, 2-DG or 3-BP for 24 hours. 90 ul of the ATP 
reaction mix was added to each well and gently mixed. 
Samples were then incubated for 10-20 min, in the dark, 
at room temperature. The luminescence intensity was 
monitored with a plate reader from Tecan. ATP levels were 
normalized based on the viable cell counts measured by 
MTT assay. Each experiment was performed in triplicate 
and repeated twice.
Cell cycle analysis
The  effect  of  glucose,  2-DG  and  3-BP  on  cell 
cycle progression was determined using Cellometer 
(Nexcelom,  Lawrence,  MA).  Cells  were  plated  at  a 
density of 1.5 × 105 cells/well in 6-well plates overnight 





day of analysis, the cells were washed with PBS and 
centrifuged. Cells were then resuspended in 50 ul RNase 
A solution (250 ug/ml) with 10 mM EDTA, followed 
by incubation for 30 min at 37°C. After incubation, 50 
μl propidium iodide (PI) staining solution (2 mg/ml PI, 
0.1 mg/ml Azide, and 0.05% Triton X-100) was added 
to each tube and incubated for 10 min in the dark. The 
cells were then assessed by Cellometer. The results 
were analyzed using FCS4 express software (Molecular 
Devices, Sunnyvale, CA).
Annexin V assay
The expression of Annixin V was detected using 
the Annexin-V FITC kit, according to the manufacturer’s 




trypsin without EDTA. After PBS washing, the cells 
were resuspended in 100 ul of Annexin-V and PI dual-
stain solution (0.1 ug of Annexin-V FITC and 1 ug of PI) 
for 15 min in the dark and detected by Cellometer. The 
results were analyzed by the FCS4 express software. Each 
experiment was repeated at least twice for consistency of 
response.
Cleaved caspase 3 assay
Cleaved caspase 3 was assessed with the Cleaved 
Caspase 3 Activity Assay kit. After treatment of the cells 
with different concentrations of glucose or V-ZAD in 96-
well plates (6000 cells/well), 10 ul of caspase 3 assay 
loading buffer was added into each well, mixed gently 
and then the plates were incubated for 60 min at 37°C, 
5%  CO2.  The  fluorescence  intensity  was  measured  at 
an excitation wavelength of 350 nm and an emission 
wavelength of 450 nm using a plate reader from Tecan.
Western blot analysis
Total protein was extracted from the ovarian cancer 
cells using RIPA buffer (Boston Bioproducts, Ashland, 
MA). Protein samples with equal loading (30 ug) were 
separated  by  10-12%  SDS-PAGE  and  transferred  onto 
PVDF membranes. The membranes were blocked with 
5% nonfat milk and then incubated with a 1: 000 dilution 
of primary antibodies overnight at 4°C. The membranes 
were washed and incubated with a secondary peroxidase-
conjugated antibody for 1 hour at room temperature. The 
membranes were developed using an enhanced ECL at 
Alpha Innotech Imaging System (Protein Simple, Santa 
Clara, CA). After developing, the membranes were 
re-probed  using  antibody  against  α-tubulin  or  β-actin 
to  confirm  equal  loading.  The  bands’  intensity  were 
measured and normalized to α-tubulin. Each experiment 
was repeated at least twice for consistency of results.
Statistical analysis
Data are expressed as mean ± SEM. Data were 
compared using two-tailed Student’s t-test, and p < 0.05 
was considered statistically significant.
Statistical analysis on synergy was analyzed by 
CalcuSyn (Biosoft, Cambridge, UK). The combination 
index (CI) of < 1 specifies a synergistic activity; whereas a 
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